The inhibition of HBO1 with WM-3835 suppressed leukemic growth in vitro and improved outcomes in mouse models, highlighting its potential as a therapeutic target in pediatric B-ALL [66]. Here, KAT7 is linked to precursor B-cell acute lymphoblastic leukemia.